More news about Solara Active Pharma Sciences - PP
16Aug 25
Solara Active Pharma Receives Rs. 4.88 Crore in First Call Money, Converts Partly Paid-Up Rights Shares
Solara Active Pharma has received Rs. 4.88 crore as first call money for 3,71,779 partly paid-up rights equity shares. The Rights Issue Committee approved the conversion of these shares from Rs. 3.50 to Rs. 7.00 paid-up per share. This has increased the company's paid-up capital to Rs. 44.47 crore. The company will now proceed with necessary steps for corporate actions and obtain listing approvals for the converted shares.
29Jul 25
Solara Active Pharma Sciences Reports Strong Q1 Results with 15% Revenue Growth
Solara Active Pharma Sciences Limited reported robust Q1 financial results with revenue of INR320.00 crores, marking a 15% quarter-on-quarter growth. The company achieved a gross margin of 54% and EBITDA of INR57.00 crores. Profit After Tax reached INR105.00 million, the highest in 12 quarters, with EPS at INR2.50. Developed markets contributed 77% of total sales. The company reduced its debt by INR143.00 crores, bringing the net debt-to-EBITDA ratio to 2.7x. Management provided guidance for FY26, projecting 10% revenue growth and 15-20% EBITDA growth. Solara plans to carve out its CRAMS and polymer business into a separate entity, transferring INR200.00 crores of debt.
25Jul 25
Solara Active Pharma Reports Strong Q1 Results with 36% EBITDA Growth
Solara Active Pharma Sciences Limited reported strong Q1 financial results. Revenue stood at Rs 319.15 crores, down 12% YoY but up 15% QoQ. EBITDA increased by 36% YoY to Rs 57.50 crores, with margins improving from 11.60% to 18.00%. The company turned profitable with a PAT of Rs 10.52 crores, compared to a loss in the previous year. Gross margins expanded from 44.50% to 54.10%. Regulated markets contributed 77% of total revenues. Solara reduced its gross debt to Rs 632.70 crores from Rs 776.00 crores in the previous quarter. The company appointed Rajesh Patro as Chief Risk Officer and is exploring the demerger of its CRAMS and Polymers business.